ARTICLE | Clinical News
Opicinumab: Phase II data
June 13, 2016 7:00 AM UTC
Top-line data from the double-blind, international Phase II SYNERGY trial in 418 patients with relapsing forms of MS, including relapsing-remitting MS (RRMS) and secondary progressive MS, showed that ...